Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 152

1.

Piloting a surveillance system for HIV drug resistance in the European Union.

van de Laar MJ, Bosman A, Pharris A, Andersson E, Assoumou L, Ay E, Bannert N, Bartmeyer B, Brady M, Chaix ML, Descamps D, Dauwe K, Fonager J, Hauser A, Lunar M, Mezei M, Neary M, Poljak M, van Sighem A, Verhofstede C, Amato-Gauci AJ, Broberg EK.

Euro Surveill. 2019 May;24(19). doi: 10.2807/1560-7917.ES.2019.24.19.1800390.

2.

Reconstruction of the Genetic History and the Current Spread of HIV-1 Subtype A in Germany.

Hanke K, Faria NR, Kühnert D, Yousef KP, Hauser A, Meixenberger K, Hofmann A, Bremer V, Bartmeyer B, Pybus O, Kücherer C, von Kleist M, Bannert N.

J Virol. 2019 May 29;93(12). pii: e02238-18. doi: 10.1128/JVI.02238-18. Print 2019 Jun 15.

PMID:
30944175
3.

Characterization of a hepatitis C virus genotype 1 divergent isolate from an HIV-1 coinfected individual in Germany assigned to a new subtype 1o.

Wang B, Krüger L, Machnowska P, Eshetu A, Gunsenheimer-Bartmeyer B, Bremer V, Hauser A, Bannert N, Bock CT.

Virol J. 2019 Mar 4;16(1):28. doi: 10.1186/s12985-019-1135-7.

4.

Human SAMHD1 restricts the xenotransplantation relevant porcine endogenous retrovirus (PERV) in non-dividing cells.

Al-Shehabi H, Fiebig U, Kutzner J, Denner J, Schaller T, Bannert N, Hofmann H.

J Gen Virol. 2019 Apr;100(4):656-661. doi: 10.1099/jgv.0.001232. Epub 2019 Feb 15.

PMID:
30767852
5.

Evaluation of a BioRad Avidity assay for identification of recent HIV-1 infections using dried serum or plasma spots.

Hauser A, Heiden MA, Meixenberger K, Han O, Fiedler S, Hanke K, Koppe U, Hofmann A, Bremer V, Bartmeyer B, Kuecherer C, Bannert N.

J Virol Methods. 2019 Apr;266:114-120. doi: 10.1016/j.jviromet.2019.02.002. Epub 2019 Feb 7.

PMID:
30738741
6.

History of detention and the risk of hepatitis C among people who inject drugs in Germany.

Gassowski M, Nielsen S, Bannert N, Bock CT, Bremer V, Ross RS, Wenz B, Marcus U, Zimmermann R; DRUCK Study Group.

Int J Infect Dis. 2019 Apr;81:100-106. doi: 10.1016/j.ijid.2019.01.015. Epub 2019 Jan 15.

7.

Prevalence and persistence of transmitted drug resistance mutations in the German HIV-1 Seroconverter Study Cohort.

Machnowska P, Meixenberger K, Schmidt D, Jessen H, Hillenbrand H, Gunsenheimer-Bartmeyer B, Hamouda O, Kücherer C, Bannert N; German HIV-1 Seroconverter Study Group.

PLoS One. 2019 Jan 16;14(1):e0209605. doi: 10.1371/journal.pone.0209605. eCollection 2019.

8.

HIV-1 molecular transmission clusters in nine European countries and Canada: association with demographic and clinical factors.

Paraskevis D, Beloukas A, Stasinos K, Pantazis N, de Mendoza C, Bannert N, Meyer L, Zangerle R, Gill J, Prins M, d'Arminio Montforte A, Kran AB, Porter K, Touloumi G; CASCADE collaboration of EuroCoord.

BMC Med. 2019 Jan 8;17(1):4. doi: 10.1186/s12916-018-1241-1.

9.

Increasing proportions of HIV-1 non-B subtypes and of NNRTI resistance between 2013 and 2016 in Germany: Results from the national molecular surveillance of new HIV-diagnoses.

Hauser A, Hofmann A, Meixenberger K, Altmann B, Hanke K, Bremer V, Bartmeyer B, Bannert N.

PLoS One. 2018 Nov 8;13(11):e0206234. doi: 10.1371/journal.pone.0206234. eCollection 2018.

10.

Risk behaviours and viral infections among drug injecting migrants from the former Soviet Union in Germany: Results from the DRUCK-study.

Derks L, Gassowski M, Nielsen S, An der Heiden M, Bannert N, Bock CT, Bremer V, Kücherer C, Ross S, Wenz B, Marcus U, Zimmermann R; DRUCK-study group.

Int J Drug Policy. 2018 Sep;59:54-62. doi: 10.1016/j.drugpo.2018.06.011. Epub 2018 Jul 11.

PMID:
30005420
11.

Easy and accurate reconstruction of whole HIV genomes from short-read sequence data with shiver.

Wymant C, Blanquart F, Golubchik T, Gall A, Bakker M, Bezemer D, Croucher NJ, Hall M, Hillebregt M, Ong SH, Ratmann O, Albert J, Bannert N, Fellay J, Fransen K, Gourlay A, Grabowski MK, Gunsenheimer-Bartmeyer B, Günthard HF, Kivelä P, Kouyos R, Laeyendecker O, Liitsola K, Meyer L, Porter K, Ristola M, van Sighem A, Berkhout B, Cornelissen M, Kellam P, Reiss P, Fraser C; BEEHIVE Collaboration.

Virus Evol. 2018 May 18;4(1):vey007. doi: 10.1093/ve/vey007. eCollection 2018 Jan.

12.

Robust and sensitive subtype-generic HIV-1 pol genotyping for use with dried serum spots in epidemiological studies.

Hauser A, Meixenberger K, Machnowska P, Fiedler S, Hanke K, Hofmann A, Bartmeyer B, Bremer V, Bannert N, Kuecherer C.

J Virol Methods. 2018 Sep;259:32-38. doi: 10.1016/j.jviromet.2018.05.013. Epub 2018 May 31.

PMID:
29859195
13.

HERVs New Role in Cancer: From Accused Perpetrators to Cheerful Protectors.

Bannert N, Hofmann H, Block A, Hohn O.

Front Microbiol. 2018 Feb 13;9:178. doi: 10.3389/fmicb.2018.00178. eCollection 2018. Review.

14.

Molecular evolution of HIV-1 integrase during the 20 years prior to the first approval of integrase inhibitors.

Meixenberger K, Yousef KP, Smith MR, Somogyi S, Fiedler S, Bartmeyer B, Hamouda O, Bannert N, von Kleist M, Kücherer C.

Virol J. 2017 Nov 14;14(1):223. doi: 10.1186/s12985-017-0887-1.

15.

Temporal trends of transmitted HIV drug resistance in a multinational seroconversion cohort.

Olson A, Bannert N, Sönnerborg A, de Mendoza C, Price M, Zangerle R, Chaix ML, Prins M, Kran AB, Gill J, Paraskevis D, Porter K; for CASCADE Collaboration in EuroCoord.

AIDS. 2018 Jan 14;32(2):161-169. doi: 10.1097/QAD.0000000000001689.

PMID:
29112061
16.

A large proportion of people who inject drugs are susceptible to hepatitis B: Results from a bio-behavioural study in eight German cities.

Haussig JM, Nielsen S, Gassowski M, Bremer V, Marcus U, Wenz B, Bannert N, Bock CT, Zimmermann R; DRUCK study group.

Int J Infect Dis. 2018 Jan;66:5-13. doi: 10.1016/j.ijid.2017.10.008. Epub 2017 Oct 31.

17.

Evaluating the Impact of Functional Genetic Variation on HIV-1 Control.

McLaren PJ, Pulit SL, Gurdasani D, Bartha I, Shea PR, Pomilla C, Gupta N, Gkrania-Klotsas E, Young EH, Bannert N, Del Amo J, Gill MJ, Gilmour J, Kellam P, Kelleher AD, Sönnerborg A, Zangerle R, Post FA, Fisher M, Haas DW, Walker BD, Porter K, Goldstein DB, Sandhu MS, de Bakker PIW, Fellay J.

J Infect Dis. 2017 Nov 27;216(9):1063-1069. doi: 10.1093/infdis/jix470. Erratum in: J Infect Dis. 2018 Jun 5;218(1):171.

18.

No significant HTLV seroprevalence in German people who inject drugs.

Hohn O, Norley S, Kücherer C, Bazarbachi A, El Hajj H, Marcus U, Zimmermann R, Bannert N.

PLoS One. 2017 Aug 22;12(8):e0183496. doi: 10.1371/journal.pone.0183496. eCollection 2017.

19.

Correction: Viral genetic variation accounts for a third of variability in HIV-1 set-point viral load in Europe.

Blanquart F, Wymant C, Cornelissen M, Gall A, Bakker M, Bezemer D, Hall M, Hillebregt M, Ong SH, Albert J, Bannert N, Fellay J, Fransen K, Gourlay AJ, Grabowski MK, Gunsenheimer-Bartmeyer B, Günthard HF, Kivelä P, Kouyos R, Laeyendecker O, Liitsola K, Meyer L, Porter K, Ristola M, van Sighem A, Vanham G, Berkhout B, Kellam P, Reiss P, Fraser C; BEEHIVE collaboration.

PLoS Biol. 2017 Jul 13;15(7):e1002608. doi: 10.1371/journal.pbio.1002608. eCollection 2017 Jul.

20.

Surveillance of recent HIV infections among newly diagnosed HIV cases in Germany between 2008 and 2014.

Hofmann A, Hauser A, Zimmermann R, Santos-Hövener C, Bätzing-Feigenbaum J, Wildner S, Kücherer C, Bannert N, Hamouda O, Bremer V, Bartmeyer B.

BMC Infect Dis. 2017 Jul 11;17(1):484. doi: 10.1186/s12879-017-2585-4.

21.

Viral genetic variation accounts for a third of variability in HIV-1 set-point viral load in Europe.

Blanquart F, Wymant C, Cornelissen M, Gall A, Bakker M, Bezemer D, Hall M, Hillebregt M, Ong SH, Albert J, Bannert N, Fellay J, Fransen K, Gourlay AJ, Grabowski MK, Gunsenheimer-Bartmeyer B, Günthard HF, Kivelä P, Kouyos R, Laeyendecker O, Liitsola K, Meyer L, Porter K, Ristola M, van Sighem A, Vanham G, Berkhout B, Kellam P, Reiss P, Fraser C; BEEHIVE collaboration.

PLoS Biol. 2017 Jun 12;15(6):e2001855. doi: 10.1371/journal.pbio.2001855. eCollection 2017 Jun. Erratum in: PLoS Biol. 2017 Jul 13;15(7):e1002608.

22.

Decreased emergence of HIV-1 drug resistance mutations in a cohort of Ugandan women initiating option B+ for PMTCT.

Machnowska P, Hauser A, Meixenberger K, Altmann B, Bannert N, Rempis E, Schnack A, Decker S, Braun V, Busingye P, Rubaihayo J, Harms G, Theuring S.

PLoS One. 2017 May 31;12(5):e0178297. doi: 10.1371/journal.pone.0178297. eCollection 2017.

23.

National molecular surveillance of recently acquired HIV infections in Germany, 2013 to 2014.

Hauser A, Hofmann A, Hanke K, Bremer V, Bartmeyer B, Kuecherer C, Bannert N.

Euro Surveill. 2017 Jan 12;22(2). pii: 30436. doi: 10.2807/1560-7917.ES.2017.22.2.30436.

24.

High variability of HIV and HCV seroprevalence and risk behaviours among people who inject drugs: results from a cross-sectional study using respondent-driven sampling in eight German cities (2011-14).

Wenz B, Nielsen S, Gassowski M, Santos-Hövener C, Cai W, Ross RS, Bock CT, Ratsch BA, Kücherer C, Bannert N, Bremer V, Hamouda O, Marcus U, Zimmermann R; DRUCK Study group.

BMC Public Health. 2016 Sep 5;16:927. doi: 10.1186/s12889-016-3545-4.

25.

Concordance between self-reported and measured HIV and hepatitis C virus infection status among people who inject drugs in Germany.

Nielsen S, Gassowski M, Wenz B, Bannert N, Bock CT, Kücherer C, Ross RS, Bremer V, Marcus U, Zimmermann R; DRUCK study group.

Hepatol Med Policy. 2016 Sep 1;1:8. doi: 10.1186/s41124-016-0016-6. eCollection 2016.

26.

Correlative Förster Resonance Electron Transfer-Proximity Ligation Assay (FRET-PLA) Technique for Studying Interactions Involving Membrane Proteins.

Ivanusic D, Denner J, Bannert N.

Curr Protoc Protein Sci. 2016 Aug 1;85:29.17.1-29.17.13. doi: 10.1002/cpps.10.

PMID:
27479505
27.

The Human Antimicrobial Protein Bactericidal/Permeability-Increasing Protein (BPI) Inhibits the Infectivity of Influenza A Virus.

Pinkenburg O, Meyer T, Bannert N, Norley S, Bolte K, Czudai-Matwich V, Herold S, Gessner A, Schnare M.

PLoS One. 2016 Jun 6;11(6):e0156929. doi: 10.1371/journal.pone.0156929. eCollection 2016.

28.

Development of an antigen-capture ELISA for the detection of the p27-CA protein of HERV-K(HML-2).

Hohn O, Mostafa S, Norley S, Bannert N.

J Virol Methods. 2016 Aug;234:186-92. doi: 10.1016/j.jviromet.2016.04.016. Epub 2016 Apr 30.

PMID:
27142113
29.

HERV-K(HML-2), a seemingly silent subtenant - but still waters run deep.

Hanke K, Hohn O, Bannert N.

APMIS. 2016 Jan-Feb;124(1-2):67-87. doi: 10.1111/apm.12475. Review.

PMID:
26818263
30.

Suppressing active replication of a live attenuated simian immunodeficiency virus vaccine does not abrogate protection from challenge.

Gabriel B, Fiebig U, Hohn O, Plesker R, Coulibaly C, Cichutek K, Mühlebach MD, Bannert N, Kurth R, Norley S.

Virology. 2016 Feb;489:1-11. doi: 10.1016/j.virol.2015.11.030. Epub 2015 Dec 11.

31.

The human endogenous retrovirus K(HML-2) has a broad envelope-mediated cellular tropism and is prone to inhibition at a post-entry, pre-integration step.

Kramer P, Lausch V, Volkwein A, Hanke K, Hohn O, Bannert N.

Virology. 2016 Jan;487:121-8. doi: 10.1016/j.virol.2015.10.014. Epub 2015 Oct 27.

32.

Comparison of 454 Ultra-Deep Sequencing and Allele-Specific Real-Time PCR with Regard to the Detection of Emerging Drug-Resistant Minor HIV-1 Variants after Antiretroviral Prophylaxis for Vertical Transmission.

Hauser A, Kuecherer C, Kunz A, Dabrowski PW, Radonić A, Nitsche A, Theuring S, Bannert N, Sewangi J, Mbezi P, Dugange F, Harms G, Meixenberger K.

PLoS One. 2015 Oct 15;10(10):e0140809. doi: 10.1371/journal.pone.0140809. eCollection 2015.

33.

Serological survey of Bartonella spp., Borrelia burgdorferi, Brucella spp., Coxiella burnetii, Francisella tularensis, Leptospira spp., Echinococcus, Hanta-, TBE- and XMR-virus infection in employees of two forestry enterprises in North Rhine-Westphalia, Germany, 2011-2013.

Jurke A, Bannert N, Brehm K, Fingerle V, Kempf VA, Kömpf D, Lunemann M, Mayer-Scholl A, Niedrig M, Nöckler K, Scholz H, Splettstoesser W, Tappe D, Fischer SF.

Int J Med Microbiol. 2015 Oct;305(7):652-62. doi: 10.1016/j.ijmm.2015.08.015. Epub 2015 Aug 21.

PMID:
26422407
35.

In Silico Prediction and Experimental Confirmation of HA Residues Conferring Enhanced Human Receptor Specificity of H5N1 Influenza A Viruses.

Schmier S, Mostafa A, Haarmann T, Bannert N, Ziebuhr J, Veljkovic V, Dietrich U, Pleschka S.

Sci Rep. 2015 Jun 19;5:11434. doi: 10.1038/srep11434.

36.

HIV-1 IN/Pol recruits LEDGF/p75 into viral particles.

Desimmie BA, Weydert C, Schrijvers R, Vets S, Demeulemeester J, Proost P, Paron I, De Rijck J, Mast J, Bannert N, Gijsbers R, Christ F, Debyser Z.

Retrovirology. 2015 Feb 12;12:16. doi: 10.1186/s12977-014-0134-4.

37.

CMV-promoter driven codon-optimized expression alters the assembly type and morphology of a reconstituted HERV-K(HML-2).

Hohn O, Hanke K, Lausch V, Zimmermann A, Mostafa S, Bannert N.

Viruses. 2014 Nov 11;6(11):4332-45. doi: 10.3390/v6114332.

38.

A simple procedure to analyze positions of interest in infectious cell cultures by correlative light and electron microscopy.

Madela K, Banhart S, Zimmermann A, Piesker J, Bannert N, Laue M.

Methods Cell Biol. 2014;124:93-110. doi: 10.1016/B978-0-12-801075-4.00005-7.

PMID:
25287838
39.

A multicentre sero-behavioural survey for hepatitis B and C, HIV and HTLV among people who inject drugs in Germany using respondent driven sampling.

Zimmermann R, Marcus U, Schäffer D, Leicht A, Wenz B, Nielsen S, Santos-Hövener C, Ross RS, Stambouli O, Ratsch BA, Bannert N, Bock CT, Kücherer C, Hamouda O.

BMC Public Health. 2014 Aug 14;14:845. doi: 10.1186/1471-2458-14-845.

40.

Assessment of ambiguous base calls in HIV-1 pol population sequences as a biomarker for identification of recent infections in HIV-1 incidence studies.

Meixenberger K, Hauser A, Jansen K, Yousef KP, Fiedler S, von Kleist M, Norley S, Somogyi S, Hamouda O, Bannert N, Bartmeyer B, Kücherer C.

J Clin Microbiol. 2014 Aug;52(8):2977-83. doi: 10.1128/JCM.03289-13. Epub 2014 Jun 11.

41.

Improved testing of recent HIV-1 infections with the BioRad avidity assay compared to the limiting antigen avidity assay and BED Capture enzyme immunoassay: evaluation using reference sample panels from the German Seroconverter Cohort.

Hauser A, Santos-Hoevener C, Meixenberger K, Zimmermann R, Somogyi S, Fiedler S, Hofmann A, Bartmeyer B, Jansen K, Hamouda O, Bannert N, Kuecherer C.

PLoS One. 2014 Jun 3;9(6):e98038. doi: 10.1371/journal.pone.0098038. eCollection 2014.

42.

Silicon nitride grids are compatible with correlative negative staining electron microscopy and tip-enhanced Raman spectroscopy for use in the detection of micro-organisms.

Lausch V, Hermann P, Laue M, Bannert N.

J Appl Microbiol. 2014 Jun;116(6):1521-30. doi: 10.1111/jam.12492. Epub 2014 Mar 31.

43.

A novel small animal model to study the replication of simian foamy virus in vivo.

Blochmann R, Curths C, Coulibaly C, Cichutek K, Kurth R, Norley S, Bannert N, Fiebig U.

Virology. 2014 Jan 5;448:65-73. doi: 10.1016/j.virol.2013.09.027. Epub 2013 Oct 18.

44.

Identification of late assembly domains of the human endogenous retrovirus-K(HML-2).

Chudak C, Beimforde N, George M, Zimmermann A, Lausch V, Hanke K, Bannert N.

Retrovirology. 2013 Nov 19;10:140. doi: 10.1186/1742-4690-10-140.

45.

HERV-K(HML-2), the Best Preserved Family of HERVs: Endogenization, Expression, and Implications in Health and Disease.

Hohn O, Hanke K, Bannert N.

Front Oncol. 2013 Sep 20;3:246. doi: 10.3389/fonc.2013.00246. Review.

46.

Staufen-1 interacts with the human endogenous retrovirus family HERV-K(HML-2) rec and gag proteins and increases virion production.

Hanke K, Hohn O, Liedgens L, Fiddeke K, Wamara J, Kurth R, Bannert N.

J Virol. 2013 Oct;87(20):11019-30. doi: 10.1128/JVI.03031-12. Epub 2013 Aug 7.

47.

LEDGINs inhibit late stage HIV-1 replication by modulating integrase multimerization in the virions.

Desimmie BA, Schrijvers R, Demeulemeester J, Borrenberghs D, Weydert C, Thys W, Vets S, Van Remoortel B, Hofkens J, De Rijck J, Hendrix J, Bannert N, Gijsbers R, Christ F, Debyser Z.

Retrovirology. 2013 May 30;10:57. doi: 10.1186/1742-4690-10-57.

48.

Depletion of cognate charged transfer RNA causes translational frameshifting within the expanded CAG stretch in huntingtin.

Girstmair H, Saffert P, Rode S, Czech A, Holland G, Bannert N, Ignatova Z.

Cell Rep. 2013 Jan 31;3(1):148-59. doi: 10.1016/j.celrep.2012.12.019. Epub 2013 Jan 24.

49.

FliA expression analysis and influence of the regulatory proteins RpoN, FleQ and FliA on virulence and in vivo fitness in Legionella pneumophila.

Schulz T, Rydzewski K, Schunder E, Holland G, Bannert N, Heuner K.

Arch Microbiol. 2012 Dec;194(12):977-89. doi: 10.1007/s00203-012-0833-y. Epub 2012 Aug 5.

PMID:
23011748
50.

Influenza A viruses target type II pneumocytes in the human lung.

Weinheimer VK, Becher A, Tönnies M, Holland G, Knepper J, Bauer TT, Schneider P, Neudecker J, Rückert JC, Szymanski K, Temmesfeld-Wollbrueck B, Gruber AD, Bannert N, Suttorp N, Hippenstiel S, Wolff T, Hocke AC.

J Infect Dis. 2012 Dec 1;206(11):1685-94. doi: 10.1093/infdis/jis455. Epub 2012 Jul 24.

PMID:
22829640

Supplemental Content

Loading ...
Support Center